Literature DB >> 7749792

Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection.

D M Simpson1, M Tagliati.   

Abstract

Peripheral nerve disorders are among the most common neurological complications of HIV disease. Distal sensory polyneuropathy (DSP) is the most common form of neuropathy in patients with AIDS and can be caused by diverse mechanisms, including infectious, metabolic, inflammatory, nutritional, and toxic factors. Antiretroviral agents may cause or contribute to HIV-related DSP. Recognition of peripheral neuropathy has become increasingly important as more patients receive nucleoside analogue agents for the treatment of HIV disease. It is crucial to correctly distinguish between the neuropathies caused by toxic effects of nucleoside analogues and those that are primarily related to underlying HIV disease, because timely diagnosis and proper treatment of peripheral neuropathies may allow the continuation of antiretroviral therapy as well as improve the quality of life. The identification and treatment of peripheral neuropathies associated with use of the nucleoside drugs zalcitabine (ddC), didanosine (ddI), and stavudine (d4T) are reviewed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7749792

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN: 1077-9450


  40 in total

1.  Alcohol consumption enhances antiretroviral painful peripheral neuropathy by mitochondrial mechanisms.

Authors:  Luiz F Ferrari; Jon D Levine
Journal:  Eur J Neurosci       Date:  2010-08-19       Impact factor: 3.386

2.  Anti-adenoviral effect of anti-HIV agents in vitro in serotypes inducing keratoconjunctivitis.

Authors:  Eiichi Uchio; Aki Fuchigami; Kazuaki Kadonosono; Akio Hayashi; Hiroaki Ishiko; Koki Aoki; Shigeaki Ohno
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-01-17       Impact factor: 3.117

Review 3.  Acetyl-L-carnitine in HIV-associated antiretroviral toxic neuropathy.

Authors:  Mike Youle
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 4.  HIV-associated neuropathic pain: epidemiology, pathophysiology and management.

Authors:  Susama Verma; Lydia Estanislao; David Simpson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

5.  Incident neuropathy in HIV-infected patients on HAART.

Authors:  Beau K Nakamoto; Aaron McMurtray; James Davis; Victor Valcour; Michael R Watters; Bruce Shiramizu; Dominic C Chow; Kalpana Kallianpur; Cecilia M Shikuma
Journal:  AIDS Res Hum Retroviruses       Date:  2010-07       Impact factor: 2.205

Review 6.  Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.

Authors:  J C Adkins; D H Peters; D Faulds
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

7.  Substance abuse increases the risk of neuropathy in an HIV-infected cohort.

Authors:  Jessica Robinson-Papp; Benjamin B Gelman; Igor Grant; Elyse Singer; Gary Gensler; Susan Morgello
Journal:  Muscle Nerve       Date:  2012-04       Impact factor: 3.217

Review 8.  Neuromuscular complications in HIV.

Authors:  Susama Verma; Elena Micsa; Lydia Estanislao; David Simpson
Journal:  Curr Neurol Neurosci Rep       Date:  2004-01       Impact factor: 5.081

Review 9.  Neuromuscular diseases associated with HIV-1 infection.

Authors:  Jessica Robinson-Papp; David M Simpson
Journal:  Muscle Nerve       Date:  2009-12       Impact factor: 3.217

Review 10.  Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management.

Authors:  G J Moyle; M Sadler
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.